Technical Data
I1904-83A
IgG2a, Heavy Chain
Description:
Applications:
Suitable for use in ELISA. Other applications not tested.

Recommended Dilutions:
ELISA: 5ug/ml as coating antibody.
Optimal working dilutions to be determined by researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG13H2371Affinity Purified
SizeStorageShippingSourceHost
250ug-20CBlue IceMouseRat
Concentration:
~1mg/ml
Immunogen:
Purified IgG from BALB/c mice.
Purity:
Purified by affinity chromatography.
Form
Supplied as a liquid in PBS, 0.1% sodium azide.
Specificity:
Recognizes the mouse gamma 2a immunoglobulin heavy chain. Recognizes an allotypic determinant upon mouse IgG2a. Reacts with the IgHIa allotype (as expressed in BALB/c mice). Does not react with the IgHIb allotype (as expressed in C57/BL mice).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Jarman, E., et al., Immunology 112: 631-642 (2004). 2. Bazin, H., (1982) Production of rat monoclonal antibodies with the LOU rat non secreting IR983F myeloma cell line. Prot. Biol. Fluids. 615-618. Pergamon Press, Oxford and New York. 3. Bazin, H., et al., J. Immunol. Methods 66: 261-269. (1984) 4. Bazin, H., et al., J. Immunol. Methods. 71: 9-16 (1984). 5. Querinjean, P., et al., Eur. J. Biochem. 31: 354-359 (1972). 6. Nagao, K., et al., Am. J. Respir. Cell. Mol. Biol. 29: 314-320 (2003). 7. Ramos, J.D.A., et al., Philippine Science Letters 2: 38-48 (2009). 8. Ormstad, H., et al., Toxicology 188: 309-318 (2003). 9. Ormstad, H., et al., J. Toxicol. Environ. Health A 61: 55-67 (2000). 10. Hall, G., et al., Vaccine 21: 549-561 (2003). 11. Tan, L.K., et al., Vaccine 24: 5762-5771 (2006). 12. Instanes, C. & Hetland, G., Toxicology 204: 13-21 (2004). 13. Lieden, A., et al., Allergy 64: 304-311 (2009). 14. Wolfowicz, C.B., et al., Vaccine 21: 1195-1204 (2003).